Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 28. More products

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

18 general benefit · 6 not a benefit

Other products in the same Health Canada class (N04B) — coverage varies; not interchangeable

  • Entacapone (Comtan): limited Use 367

Act Pramipexole · DIN 02297302 · 0.25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Pramipexole · DIN 02297302 Manufacturer: Teva Canada Limited; listing date 2009-06-23 Health Canada: Marketed since 2020-04-27 · brand ACT PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.25 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Act Pramipexole: Formulary list price $0.1950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78267 · Verify on the e-Formulary ↗ (DIN 02297302)

Source record
DIN 02297302: Act Pramipexole Raw flags: sec3=Y Item: 289200001; group id 543; item number 1462; lccId None; manufacturer id TEV Source form: Tab; strength: 0.25mg Recorded listing: General benefit Source prices (unrounded): $0.1950; ministry $0.1950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02297302 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78267
Interchangeable products
Apo-Pramipexole · DIN 02292378 · $0.1950 Auro-Pramipexole · DIN 02424061 · $0.1950 Mirapex · DIN 02237145 · $0.1950 Pramipexole · DIN 02309122 · $0.1950 Pramipexole · DIN 02367602 · $0.1950 Sandoz Pramipexole · DIN 02315262 · $0.1950
Shortage status: active shortage (reported 2026-02-04, last updated 2026-02-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02297302
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Pramipexole · DIN 02292378 · 0.25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Pramipexole · DIN 02292378 Manufacturer: Apotex Inc.; listing date 2007-04-02 Health Canada: Marketed since 2007-02-26 · brand APO-PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.25 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Pramipexole: Formulary list price $0.1950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77772 · Verify on the e-Formulary ↗ (DIN 02292378)

Source record
DIN 02292378: Apo-Pramipexole Raw flags: sec3=Y Item: 289200001; group id 543; item number 1462; lccId None; manufacturer id APX Source form: Tab; strength: 0.25mg Recorded listing: General benefit Source prices (unrounded): $0.1950; ministry $0.1950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02292378 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77772
Interchangeable products
Act Pramipexole · DIN 02297302 · $0.1950 Auro-Pramipexole · DIN 02424061 · $0.1950 Mirapex · DIN 02237145 · $0.1950 Pramipexole · DIN 02309122 · $0.1950 Pramipexole · DIN 02367602 · $0.1950 Sandoz Pramipexole · DIN 02315262 · $0.1950
Shortage status: active shortage (reported 2026-06-16, estimated to end 2026-09-18, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292378
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Pramipexole · DIN 02424061 · 0.25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Pramipexole · DIN 02424061 Manufacturer: Auro Pharma Inc.; listing date 2014-06-26 Health Canada: Marketed since 2014-04-29 · brand AURO-PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.25 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Pramipexole: Formulary list price $0.1950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90879 · Verify on the e-Formulary ↗ (DIN 02424061)

Source record
DIN 02424061: Auro-Pramipexole Raw flags: sec3=Y Item: 289200001; group id 543; item number 1462; lccId None; manufacturer id AUR Source form: Tab; strength: 0.25mg Recorded listing: General benefit Source prices (unrounded): $0.1950; ministry $0.1950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02424061 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90879
Interchangeable products
Act Pramipexole · DIN 02297302 · $0.1950 Apo-Pramipexole · DIN 02292378 · $0.1950 Mirapex · DIN 02237145 · $0.1950 Pramipexole · DIN 02309122 · $0.1950 Pramipexole · DIN 02367602 · $0.1950 Sandoz Pramipexole · DIN 02315262 · $0.1950
Shortage status: resolved shortage (ended 2024-03-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02424061
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mirapex · DIN 02237145 · 0.25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mirapex · DIN 02237145 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2000-04-17 Health Canada: Marketed since 1998-02-26 · brand MIRAPEX · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.25 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60463 · Verify on the e-Formulary ↗ (DIN 02237145)

Source record
DIN 02237145: Mirapex Raw flags: sec3=Y Item: 289200001; group id 543; item number 1462; lccId None; manufacturer id BOE Source form: Tab; strength: 0.25mg Recorded listing: General benefit Source prices (unrounded): $1.3474; ministry $0.1950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237145 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60463
Interchangeable products
Act Pramipexole · DIN 02297302 · $0.1950 Apo-Pramipexole · DIN 02292378 · $0.1950 Auro-Pramipexole · DIN 02424061 · $0.1950 Pramipexole · DIN 02309122 · $0.1950 Pramipexole · DIN 02367602 · $0.1950 Sandoz Pramipexole · DIN 02315262 · $0.1950
Shortage status: resolved shortage (ended 2026-05-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237145
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pramipexole · DIN 02309122 · 0.25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Pramipexole · DIN 02309122 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2018-09-13 · brand PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Pramipexole: Formulary list price $0.1950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79472 · Verify on the e-Formulary ↗ (DIN 02309122)

Source record
DIN 02309122: Pramipexole Raw flags: sec3=Y Item: 289200001; group id 543; item number 1462; lccId None; manufacturer id SIV Source form: Tab; strength: 0.25mg Recorded listing: General benefit Source prices (unrounded): $0.1950; ministry $0.1950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02309122 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79472
Interchangeable products
Act Pramipexole · DIN 02297302 · $0.1950 Apo-Pramipexole · DIN 02292378 · $0.1950 Auro-Pramipexole · DIN 02424061 · $0.1950 Mirapex · DIN 02237145 · $0.1950 Pramipexole · DIN 02367602 · $0.1950 Sandoz Pramipexole · DIN 02315262 · $0.1950
Shortage status: resolved shortage (ended 2018-12-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02309122
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pramipexole · DIN 02367602 · 0.25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Pramipexole · DIN 02367602 Manufacturer: Sanis Health Inc.; listing date 2022-06-30 Health Canada: Marketed since 2022-03-28 · brand PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.25 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Pramipexole: Formulary list price $0.1950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85244 · Verify on the e-Formulary ↗ (DIN 02367602)

Source record
DIN 02367602: Pramipexole Raw flags: sec3=Y Item: 289200001; group id 543; item number 1462; lccId None; manufacturer id SAI Source form: Tab; strength: 0.25mg Recorded listing: General benefit Source prices (unrounded): $0.1950; ministry $0.1950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02367602 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85244
Interchangeable products
Act Pramipexole · DIN 02297302 · $0.1950 Apo-Pramipexole · DIN 02292378 · $0.1950 Auro-Pramipexole · DIN 02424061 · $0.1950 Mirapex · DIN 02237145 · $0.1950 Pramipexole · DIN 02309122 · $0.1950 Sandoz Pramipexole · DIN 02315262 · $0.1950
Shortage status: resolved shortage (ended 2025-04-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02367602
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Pramipexole · DIN 02315262 · 0.25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Pramipexole · DIN 02315262 Manufacturer: Sandoz Canada Inc.; listing date 2008-11-04 Health Canada: Marketed since 2008-08-14 · brand SANDOZ PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.25 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Pramipexole: Formulary list price $0.1950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80080 · Verify on the e-Formulary ↗ (DIN 02315262)

Source record
DIN 02315262: Sandoz Pramipexole Raw flags: sec3=Y Item: 289200001; group id 543; item number 1462; lccId None; manufacturer id SDZ Source form: Tab; strength: 0.25mg Recorded listing: General benefit Source prices (unrounded): $0.1950; ministry $0.1950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02315262 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80080
Interchangeable products
Act Pramipexole · DIN 02297302 · $0.1950 Apo-Pramipexole · DIN 02292378 · $0.1950 Auro-Pramipexole · DIN 02424061 · $0.1950 Mirapex · DIN 02237145 · $0.1950 Pramipexole · DIN 02309122 · $0.1950 Pramipexole · DIN 02367602 · $0.1950
Shortage status: resolved shortage (ended 2022-06-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02315262
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Act Pramipexole · DIN 02297329 · 1mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Act Pramipexole · DIN 02297329 Manufacturer: Teva Canada Limited; listing date 2009-06-23 Health Canada: Marketed since 2020-04-27 · brand ACT PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Act Pramipexole: Formulary list price $0.3901/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3901 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78269 · Verify on the e-Formulary ↗ (DIN 02297329)

Source record
DIN 02297329: Act Pramipexole Raw flags: sec3=Y Item: 289200024; group id 543; item number 1464; lccId None; manufacturer id TEV Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.3901; ministry $0.3901 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02297329 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78269
Interchangeable products
Apo-Pramipexole · DIN 02292394 · $0.3901 Auro-Pramipexole · DIN 02424096 · $0.3901 Mirapex · DIN 09857269 · not recorded Pramipexole · DIN 02309149 · $0.3901 Pramipexole · DIN 02367629 · $0.3901 Sandoz Pramipexole · DIN 02315289 · $0.3901
Shortage status: resolved shortage (ended 2024-01-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02297329
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Pramipexole · DIN 02292394 · 1mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Pramipexole · DIN 02292394 Manufacturer: Apotex Inc.; listing date 2007-04-02 Health Canada: Marketed since 2007-02-26 · brand APO-PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1.0 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Pramipexole: Formulary list price $0.3901/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3901 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77774 · Verify on the e-Formulary ↗ (DIN 02292394)

Source record
DIN 02292394: Apo-Pramipexole Raw flags: sec3=Y Item: 289200024; group id 543; item number 1464; lccId None; manufacturer id APX Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.3901; ministry $0.3901 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02292394 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77774
Interchangeable products
Act Pramipexole · DIN 02297329 · $0.3901 Auro-Pramipexole · DIN 02424096 · $0.3901 Mirapex · DIN 09857269 · not recorded Pramipexole · DIN 02309149 · $0.3901 Pramipexole · DIN 02367629 · $0.3901 Sandoz Pramipexole · DIN 02315289 · $0.3901
Shortage status: active shortage (reported 2026-08-05, estimated to end 2026-09-18, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292394
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Pramipexole · DIN 02424096 · 1mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Pramipexole · DIN 02424096 Manufacturer: Auro Pharma Inc.; listing date 2014-06-26 Health Canada: Marketed since 2014-04-29 · brand AURO-PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Pramipexole: Formulary list price $0.3901/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3901 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90881 · Verify on the e-Formulary ↗ (DIN 02424096)

Source record
DIN 02424096: Auro-Pramipexole Raw flags: sec3=Y Item: 289200024; group id 543; item number 1464; lccId None; manufacturer id AUR Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.3901; ministry $0.3901 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02424096 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90881
Interchangeable products
Act Pramipexole · DIN 02297329 · $0.3901 Apo-Pramipexole · DIN 02292394 · $0.3901 Mirapex · DIN 09857269 · not recorded Pramipexole · DIN 02309149 · $0.3901 Pramipexole · DIN 02367629 · $0.3901 Sandoz Pramipexole · DIN 02315289 · $0.3901
Shortage status: resolved shortage (ended 2024-03-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02424096
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pramipexole · DIN 02309149 · 1mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pramipexole · DIN 02309149 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2018-11-23 · brand PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Pramipexole: Formulary list price $0.3901/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3901 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79474 · Verify on the e-Formulary ↗ (DIN 02309149)

Source record
DIN 02309149: Pramipexole Raw flags: sec3=Y Item: 289200024; group id 543; item number 1464; lccId None; manufacturer id SIV Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.3901; ministry $0.3901 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02309149 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79474
Interchangeable products
Act Pramipexole · DIN 02297329 · $0.3901 Apo-Pramipexole · DIN 02292394 · $0.3901 Auro-Pramipexole · DIN 02424096 · $0.3901 Mirapex · DIN 09857269 · not recorded Pramipexole · DIN 02367629 · $0.3901 Sandoz Pramipexole · DIN 02315289 · $0.3901
Shortage status: resolved shortage (ended 2018-12-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02309149
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pramipexole · DIN 02367629 · 1mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pramipexole · DIN 02367629 Manufacturer: Sanis Health Inc.; listing date 2022-06-30 Health Canada: Marketed since 2022-03-28 · brand PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Pramipexole: Formulary list price $0.3901/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3901 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85247 · Verify on the e-Formulary ↗ (DIN 02367629)

Source record
DIN 02367629: Pramipexole Raw flags: sec3=Y Item: 289200024; group id 543; item number 1464; lccId None; manufacturer id SAI Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.3901; ministry $0.3901 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02367629 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85247
Interchangeable products
Act Pramipexole · DIN 02297329 · $0.3901 Apo-Pramipexole · DIN 02292394 · $0.3901 Auro-Pramipexole · DIN 02424096 · $0.3901 Mirapex · DIN 09857269 · not recorded Pramipexole · DIN 02309149 · $0.3901 Sandoz Pramipexole · DIN 02315289 · $0.3901
Shortage status: discontinued (2019-03-26, reported by SANIS HEALTH INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02367629
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Pramipexole · DIN 02315289 · 1mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Pramipexole · DIN 02315289 Manufacturer: Sandoz Canada Inc.; listing date 2008-11-04 Health Canada: Marketed since 2008-08-14 · brand SANDOZ PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Pramipexole: Formulary list price $0.3901/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3901 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80082 · Verify on the e-Formulary ↗ (DIN 02315289)

Source record
DIN 02315289: Sandoz Pramipexole Raw flags: sec3=Y Item: 289200024; group id 543; item number 1464; lccId None; manufacturer id SDZ Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.3901; ministry $0.3901 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02315289 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80082
Interchangeable products
Act Pramipexole · DIN 02297329 · $0.3901 Apo-Pramipexole · DIN 02292394 · $0.3901 Auro-Pramipexole · DIN 02424096 · $0.3901 Mirapex · DIN 09857269 · not recorded Pramipexole · DIN 02309149 · $0.3901 Pramipexole · DIN 02367629 · $0.3901
Shortage status: resolved shortage (ended 2025-04-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02315289
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Act Pramipexole · DIN 02297337 · 1.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Act Pramipexole · DIN 02297337 Manufacturer: Teva Canada Limited; listing date 2009-06-23 Health Canada: Marketed since 2020-04-27 · brand ACT PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1.5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Act Pramipexole: Formulary list price $0.3901/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3901 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78270 · Verify on the e-Formulary ↗ (DIN 02297337)

Source record
DIN 02297337: Act Pramipexole Raw flags: sec3=Y Item: 289200025; group id 543; item number 1465; lccId None; manufacturer id TEV Source form: Tab; strength: 1.5mg Recorded listing: General benefit Source prices (unrounded): $0.3901; ministry $0.3901 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02297337 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78270
Interchangeable products
Apo-Pramipexole · DIN 02292408 · $0.3901 Auro-Pramipexole · DIN 02424118 · $0.3901 Mirapex · DIN 09857270 · not recorded Pramipexole · DIN 02309157 · $0.3901 Pramipexole · DIN 02367645 · $0.3901 Sandoz Pramipexole · DIN 02315297 · $0.3901
Shortage status: resolved shortage (ended 2025-10-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02297337
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Pramipexole · DIN 02292408 · 1.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Pramipexole · DIN 02292408 Manufacturer: Apotex Inc.; listing date 2007-04-02 Health Canada: Marketed since 2007-02-26 · brand APO-PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Pramipexole: Formulary list price $0.3901/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3901 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77776 · Verify on the e-Formulary ↗ (DIN 02292408)

Source record
DIN 02292408: Apo-Pramipexole Raw flags: sec3=Y Item: 289200025; group id 543; item number 1465; lccId None; manufacturer id APX Source form: Tab; strength: 1.5mg Recorded listing: General benefit Source prices (unrounded): $0.3901; ministry $0.3901 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02292408 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77776
Interchangeable products
Act Pramipexole · DIN 02297337 · $0.3901 Auro-Pramipexole · DIN 02424118 · $0.3901 Mirapex · DIN 09857270 · not recorded Pramipexole · DIN 02309157 · $0.3901 Pramipexole · DIN 02367645 · $0.3901 Sandoz Pramipexole · DIN 02315297 · $0.3901
Shortage status: active shortage (reported 2026-03-03, estimated to end 2026-09-18, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292408
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Pramipexole · DIN 02424118 · 1.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Pramipexole · DIN 02424118 Manufacturer: Auro Pharma Inc.; listing date 2014-06-26 Health Canada: Marketed since 2014-04-29 · brand AURO-PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1.5 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Pramipexole: Formulary list price $0.3901/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3901 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90882 · Verify on the e-Formulary ↗ (DIN 02424118)

Source record
DIN 02424118: Auro-Pramipexole Raw flags: sec3=Y Item: 289200025; group id 543; item number 1465; lccId None; manufacturer id AUR Source form: Tab; strength: 1.5mg Recorded listing: General benefit Source prices (unrounded): $0.3901; ministry $0.3901 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02424118 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90882
Interchangeable products
Act Pramipexole · DIN 02297337 · $0.3901 Apo-Pramipexole · DIN 02292408 · $0.3901 Mirapex · DIN 09857270 · not recorded Pramipexole · DIN 02309157 · $0.3901 Pramipexole · DIN 02367645 · $0.3901 Sandoz Pramipexole · DIN 02315297 · $0.3901
Shortage status: resolved shortage (ended 2024-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02424118
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pramipexole · DIN 02309157 · 1.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pramipexole · DIN 02309157 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2018-11-23 · brand PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Pramipexole: Formulary list price $0.3901/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3901 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79475 · Verify on the e-Formulary ↗ (DIN 02309157)

Source record
DIN 02309157: Pramipexole Raw flags: sec3=Y Item: 289200025; group id 543; item number 1465; lccId None; manufacturer id SIV Source form: Tab; strength: 1.5mg Recorded listing: General benefit Source prices (unrounded): $0.3901; ministry $0.3901 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02309157 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79475
Interchangeable products
Act Pramipexole · DIN 02297337 · $0.3901 Apo-Pramipexole · DIN 02292408 · $0.3901 Auro-Pramipexole · DIN 02424118 · $0.3901 Mirapex · DIN 09857270 · not recorded Pramipexole · DIN 02367645 · $0.3901 Sandoz Pramipexole · DIN 02315297 · $0.3901
Shortage status: resolved shortage (ended 2018-12-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02309157
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Pramipexole · DIN 02315297 · 1.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Pramipexole · DIN 02315297 Manufacturer: Sandoz Canada Inc.; listing date 2008-11-04 Health Canada: Marketed since 2008-08-14 · brand SANDOZ PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1.5 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Pramipexole: Formulary list price $0.3901/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3901 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80083 · Verify on the e-Formulary ↗ (DIN 02315297)

Source record
DIN 02315297: Sandoz Pramipexole Raw flags: sec3=Y Item: 289200025; group id 543; item number 1465; lccId None; manufacturer id SDZ Source form: Tab; strength: 1.5mg Recorded listing: General benefit Source prices (unrounded): $0.3901; ministry $0.3901 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02315297 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80083
Interchangeable products
Act Pramipexole · DIN 02297337 · $0.3901 Apo-Pramipexole · DIN 02292408 · $0.3901 Auro-Pramipexole · DIN 02424118 · $0.3901 Mirapex · DIN 09857270 · not recorded Pramipexole · DIN 02309157 · $0.3901 Pramipexole · DIN 02367645 · $0.3901
Shortage status: resolved shortage (ended 2019-01-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02315297
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Act Pramipexole · DIN 02297310 · 0.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Act Pramipexole · DIN 02297310 Manufacturer: Teva Canada Limited; listing date 2009-06-23 Health Canada: Marketed since 2020-04-27 · brand ACT PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78268 · Verify on the e-Formulary ↗ (DIN 02297310)

Source record
DIN 02297310: Act Pramipexole Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200011; group id 543; item number 1463; lccId None; manufacturer id TEV Source form: Tab; strength: 0.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.3860; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02297310 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78268
Interchangeable products
Apo-Pramipexole · DIN 02292386 · not recorded Auro-Pramipexole · DIN 02424088 · not recorded Mirapex · DIN 02241594 · not recorded Pramipexole · DIN 02309130 · not recorded Pramipexole · DIN 02367610 · not recorded Sandoz Pramipexole · DIN 02315270 · not recorded
Shortage status: resolved shortage (ended 2024-01-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02297310
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Pramipexole · DIN 02292386 · 0.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Pramipexole · DIN 02292386 Manufacturer: Apotex Inc.; listing date 2007-09-04 Health Canada: Marketed since 2007-02-26 · brand APO-PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77773 · Verify on the e-Formulary ↗ (DIN 02292386)

Source record
DIN 02292386: Apo-Pramipexole Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200011; group id 543; item number 1463; lccId None; manufacturer id APX Source form: Tab; strength: 0.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.3860; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02292386 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77773
Interchangeable products
Act Pramipexole · DIN 02297310 · not recorded Auro-Pramipexole · DIN 02424088 · not recorded Mirapex · DIN 02241594 · not recorded Pramipexole · DIN 02309130 · not recorded Pramipexole · DIN 02367610 · not recorded Sandoz Pramipexole · DIN 02315270 · not recorded
Shortage status: active shortage (reported 2026-06-02, estimated to end 2026-09-18, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292386
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Pramipexole · DIN 02424088 · 0.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Pramipexole · DIN 02424088 Manufacturer: Auro Pharma Inc.; listing date 2017-05-31 Health Canada: Marketed since 2014-04-29 · brand AURO-PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.5 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90880 · Verify on the e-Formulary ↗ (DIN 02424088)

Source record
DIN 02424088: Auro-Pramipexole Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200011; group id 543; item number 1463; lccId None; manufacturer id AUR Source form: Tab; strength: 0.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.3860; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02424088 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90880
Interchangeable products
Act Pramipexole · DIN 02297310 · not recorded Apo-Pramipexole · DIN 02292386 · not recorded Mirapex · DIN 02241594 · not recorded Pramipexole · DIN 02309130 · not recorded Pramipexole · DIN 02367610 · not recorded Sandoz Pramipexole · DIN 02315270 · not recorded
Shortage status: resolved shortage (ended 2021-01-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02424088
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pramipexole · DIN 02309130 · 0.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pramipexole · DIN 02309130 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2018-09-13 · brand PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79473 · Verify on the e-Formulary ↗ (DIN 02309130)

Source record
DIN 02309130: Pramipexole Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200011; group id 543; item number 1463; lccId None; manufacturer id SIV Source form: Tab; strength: 0.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.3860; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02309130 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79473
Interchangeable products
Act Pramipexole · DIN 02297310 · not recorded Apo-Pramipexole · DIN 02292386 · not recorded Auro-Pramipexole · DIN 02424088 · not recorded Mirapex · DIN 02241594 · not recorded Pramipexole · DIN 02367610 · not recorded Sandoz Pramipexole · DIN 02315270 · not recorded
Shortage status: resolved shortage (ended 2025-06-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02309130
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pramipexole · DIN 02367610 · 0.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pramipexole · DIN 02367610 Manufacturer: Sanis Health Inc.; listing date 2022-06-30 Health Canada: Marketed since 2022-03-28 · brand PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.5 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85245 · Verify on the e-Formulary ↗ (DIN 02367610)

Source record
DIN 02367610: Pramipexole Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200011; group id 543; item number 1463; lccId None; manufacturer id SAI Source form: Tab; strength: 0.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.3860; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02367610 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85245
Interchangeable products
Act Pramipexole · DIN 02297310 · not recorded Apo-Pramipexole · DIN 02292386 · not recorded Auro-Pramipexole · DIN 02424088 · not recorded Mirapex · DIN 02241594 · not recorded Pramipexole · DIN 02309130 · not recorded Sandoz Pramipexole · DIN 02315270 · not recorded
Shortage status: discontinued (2019-03-26, reported by SANIS HEALTH INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02367610
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Pramipexole · DIN 02315270 · 0.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Pramipexole · DIN 02315270 Manufacturer: Sandoz Canada Inc.; listing date 2009-05-20 Health Canada: Marketed since 2008-08-14 · brand SANDOZ PRAMIPEXOLE · ATC N04BC05 PRAMIPEXOLE · form Tablet · route Oral · ingredients PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.5 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80081 · Verify on the e-Formulary ↗ (DIN 02315270)

Source record
DIN 02315270: Sandoz Pramipexole Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200011; group id 543; item number 1463; lccId None; manufacturer id SDZ Source form: Tab; strength: 0.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.3860; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02315270 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80081
Interchangeable products
Act Pramipexole · DIN 02297310 · not recorded Apo-Pramipexole · DIN 02292386 · not recorded Auro-Pramipexole · DIN 02424088 · not recorded Mirapex · DIN 02241594 · not recorded Pramipexole · DIN 02309130 · not recorded Pramipexole · DIN 02367610 · not recorded
Shortage status: resolved shortage (ended 2025-04-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02315270
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:92 Miscellaneous Central Nervous System Drugs) and how they are covered

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PIZOTYLINE Some products covered without a code (check the product listing): ATOMOXETINE HCL 28:92 Miscellaneous Central Nervous System Drugs

ENTACAPONE

· 4 products · Limited Use, codes 367 · strengths: 200mg · Tab

ATOMOXETINE HCL

· 59 products · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) · strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg · Cap

PIZOTYLINE

· 1 products · General benefit · strengths: 1mg · Tab

ACAMPROSATE CALCIUM

· 1 products · Limited Use, codes 531 · strengths: 333mg · DR Tab

ALMOTRIPTAN

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6.25mg, 12.5mg · Tab

DIMETHYL FUMARATE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 120mg, 240mg · DR Cap

ELETRIPTAN

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 40mg · Tab

FROVATRIPTAN SUCCINATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Tab

MEMANTINE HCL

· 11 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab

NARATRIPTAN HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2.5mg · Tab

RIZATRIPTAN

· 44 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

SUMATRIPTAN SUCCINATE

· 37 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6mg/0.5mL, 25mg, 50mg, 100mg · Inj Sol-Pref Syr 0.5mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:92 and 1 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS MIRAPEX (pramipexole dihydrochloride monohydrate) is indicated for adults, as: • treatment of the signs and symptoms of idiopathic Parkinson’s disease. MIRAPEX may be used both as early therapy, without concomitant levodopa, and as an adjunct to levodopa. • symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome. The effectiveness of MIRAPEX used for longer than 12 weeks has not been systematically evaluated in controlled trials for Restless Legs Syndrome. The physician who elects to prescribe MIRAPEX for an extended time should periodically re-evaluate the long-term usefulness for the individual patient. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): The majority of pramipexole (88%) is cleared via renal secretion. Due to age-related reduction in renal function, the elderly have a slower clearance of pramipexole (approximately 25 – 30% lower). The efficacy and safety appear to be unaffected, except the relative risk of hallucination is h… https://pdf.hres.ca/dpd_pm/00075012.PDF PM date: MAR 20, 2024 Source product: MIRAPEX; DIN 02237145; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Act Pramipexole · DIN 02297302 Shortage status: active shortage (reported 2026-02-04, last updated 2026-02-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02297302

Check this DIN again

Apo-Pramipexole · DIN 02292378 Shortage status: active shortage (reported 2026-06-16, estimated to end 2026-09-18, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292378

Check this DIN again

Apo-Pramipexole · DIN 02292394 Shortage status: active shortage (reported 2026-08-05, estimated to end 2026-09-18, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292394

Check this DIN again

Pramipexole · DIN 02367629 Shortage status: discontinued (2019-03-26, reported by SANIS HEALTH INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02367629

Check this DIN again

Apo-Pramipexole · DIN 02292408 Shortage status: active shortage (reported 2026-03-03, estimated to end 2026-09-18, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292408

Check this DIN again

Apo-Pramipexole · DIN 02292386 Shortage status: active shortage (reported 2026-06-02, estimated to end 2026-09-18, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292386

Check this DIN again

Pramipexole · DIN 02367610 Shortage status: discontinued (2019-03-26, reported by SANIS HEALTH INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02367610

Check this DIN again

Other review policies

For Act Pramipexole, Apo-Pramipexole, Auro-Pramipexole, Pramipexole, Sandoz Pramipexole: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026